NCT05136209 Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy
| NCT ID | NCT05136209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Congenital Cataract |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-11-01 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2021-11-01 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Selecting the appropriate surgical approach for congenital cataracts presents challenging for ophthalmologists. This prospective, randomized controlled study aims to compare the prognosis of posterior continuous curvilinear capsulorhexis (PCCC) with or without anterior vitrectomy (A-Vit) in treating congenital cataracts.
Eligibility Criteria
Inclusion Criteria: * Children with bilateral congenital cataracts without other ocular abnormalities * Gestational age at birth \>37 weeks * No more than 18 years old * Pupils could dilate normally pre-operation * Have signed a consent form * Can be followed Exclusion Criteria: * Intraocular pressure \>21 mmHg * History of ocular trauma and intraocular surgery
Contact & Investigator
Weirong Chen, MD
PRINCIPAL INVESTIGATOR
Zhongshan Ophthalmic Center, Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT05136209 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 18 Years, studying Congenital Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05136209 currently recruiting?
Yes, NCT05136209 is actively recruiting participants. Contact the research team at qintf3@mail2.sysu.edu.cn for enrollment information.
Where is the NCT05136209 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05136209 clinical trial?
NCT05136209 is sponsored by Sun Yat-sen University. The principal investigator is Weirong Chen, MD at Zhongshan Ophthalmic Center, Sun Yat-sen University. The trial plans to enroll 50 participants.